Vice President JD Vance delivers remarks during the annual March for Life rally on the National Mall in Washington, D.C., on Jan. 23, 2026. (Photo by Kevin Dietsch/Getty Images)

WASHINGTON — The Trump administration plans to expand a policy that blocks foreign aid dollars from going to organizations that discuss, refer or perform abortions to also include groups that address transgender health care or have policies on diversity, equity and inclusion, Vice President JD Vance said Friday.

“We’re expanding this policy to protect life, to combat DEI and the radical gender ideologies that prey on our children. And with these additions, the rule will now cover every non-military foreign assistance that America sends,” Vance announced at the March for Life anti-abortion rally on the National Mall.  

“All in all, we have expanded the Mexico City Policy about three times as big as it was before,” he added. “And we’re proud of it, because we believe in fighting for life.”

The White House did not immediately respond to a request from States Newsroom for more details on the policy expansion or when it would be implemented. 

Defending administration’s record

Vance said during the rally he needed to “address an elephant in the room” that President Donald Trump and others in the administration have not made enough progress on anti-abortion initiatives during the first year of unified Republican control of the federal government.  

“I want you to know that I hear you and that I understand,” he said. “There will inevitably be debates within this movement. We love each other. But we’re going to have open conversations about how best to use our political system to advance life, how prudential we must be in the cause of advancing human life. I think these are good, natural and honest debates.”

Vance mentioned that Trump nominated some of the Supreme Court justices that overturned Roe v. Wade, the 1973 case that had guaranteed a constitutional right to an abortion for nearly 50 years. 

He also noted that Republicans in Congress included a provision in the “big, beautiful” law that blocks Medicaid funding from going to Planned Parenthood for one year for any type of health care. Federal law had already barred funding from going to abortions, with limited exceptions.

Vance argued that in addition to judicial rulings and federal laws, members of the anti-abortion movement must strive to change hearts and minds as well. 

“We’re not trying to argue to the Supreme Court anymore,” he said. “We’re trying to argue to our fellow citizens that we must build up that culture of life. And as you know, that effort is going to take a lot of time, it’s going to take a lot of energy and it’s going to take a little bit of money.”

Later in his speech, Vance sought to discourage people from concentrating on professional lives and instead called on them to focus more on getting married and having children. 

“You’re never going to find great meaning in a cubicle or in front of a computer screen,” he said. “But you will find great meaning if you dedicate yourself to the creation and sustenance of human life.”

Trump didn’t attend the rally in person but recorded a video message that was played just before Vance spoke, telling attendees he “was proud to be the first president in history to attend this march in person” six years ago. 

“In my first term I was honored to appoint judges and justices who believed in interpreting the Constitution as written. That was a big deal. And because of that, the pro-life movement won the greatest victory in its history,” Trump said. “Now the work to rebuild a culture that supports life continues in every state, every community and every part of our beautiful land.”

Calls for action on medication abortion

Trump and some in his administration have come under scrutiny lately for not moving faster to complete a safety review of mifepristone, one of two pharmaceuticals used in medication abortion, which is approved for up to 10 weeks gestation. 

Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, and Lila Rose, founder of the anti-abortion group Live Action, both released statements in December calling on Trump to fire Food and Drug Administration Commissioner Marty Makary over the pace of that review.

Anti-abortion organizations want the administration to end the ability of doctors or other qualified health care providers to prescribe mifepristone and the second pharmaceutical used in medication abortion, misoprostol, via telehealth and have it shipped to patients. 

Several Republicans in Congress have joined their call, with Senate Health, Education, Labor and Pensions Committee Chairman Bill Cassidy, R-La., holding a hearing on mifepristone earlier this month. 

The U.S. Supreme Court rejected efforts from anti-abortion organizations to limit access to mifepristone in a June 2024 ruling, writing they never had standing to bring the lawsuit in the first place. 

Trump told House Republicans during a policy retreat at the Kennedy Center earlier this month they must be “flexible” about the Hyde Amendment, which blocks federal funding for abortion with limited exceptions, in order to broker a health care deal that can reach his desk. 

Dannenfelser rebuked Trump for the comment, writing in a statement that to “suggest Republicans should be ‘flexible’ is an abandonment of this decades-long commitment. If Republicans abandon Hyde, they are sure to lose this November.”

GOP leaders tout major law

U.S. House Speaker Mike Johnson, R-La., also spoke at the March for Life rally, touting the “big, beautiful” law as “the most pro-life and pro-family legislation that has been signed into law in decades.”

“For the first time since Roe v. Wade was reversed, we have the White House, the Senate and the House all working together to deliver meaningful and historic pro-life victories,” he said. 

The law included several policies that Johnson said will aid Americans in having children, including an expansion of the child tax credit and the adoption tax credit as well as the investment accounts for babies. 

Johnson said the provision that blocks Medicaid patients from going to Planned Parenthood for non-abortion health care services, depriving the organization of that income, was a massive policy victory for Republicans. 

“We stand here today with one united voice to affirm the federal government should not be subsidizing any industry that profits from the elimination of human life,” Johnson said. 

New Jersey Republican Rep. Chris Smith, speaking just after Johnson while other GOP lawmakers stood on the stage, said eliminating access to mifepristone must be accomplished. 

“I’ve been here since Ronald Reagan’s first election, 1981,” Smith said. “And I can tell you, this leadership is the most pro-life, so committed. And behind me are just absolute heroes. Men and women who take up the fight every single day.”

Senate Majority Leader John Thune, R-S.D., didn’t attend the rally in person but submitted a video that touted the Planned Parenthood defunding provision. 

“Thanks to that landmark legislation, this year, some of the nation’s largest abortion providers, including Planned Parenthood, are prohibited from receiving Medicaid funding,” Thune said. 

Other Republicans attending the rally included Alabama Rep. Robert Aderholt, Arkansas Rep. French Hill, Florida Rep. Kat Cammack, Georgia Rep. Andrew Clyde, Maryland Rep. Andy Harris, Michigan Reps. Bill Huizenga and Tim Walberg, Minnesota Rep. Michelle Fischbach, Missouri Rep. Bob Onder, Pennsylvania Rep. Dan Meuser, South Carolina Rep. William Timmons, Texas Reps. Michael Cloud and Dan Crenshaw, Utah Rep. Mike Kennedy, Virginia Rep. John McGuire and Wisconsin Rep. Glenn Grothman.

Louisiana Republican U.S. Sen. Bill Cassidy speaks during a press conference on Wednesday, Jan. 14, 2026. Also pictured, from left, are Family Foundation of Virginia President Victoria Cobb, National Association of Christian Lawmakers Founder and President Jason Rapert, Family Research Council President Tony Perkins, Ohio Attorney General Dave Yost, Louisiana Attorney General Liz Murrill and Missouri Republican U.S. Sen. Josh Hawley. (Photo by Jennifer Shutt/States Newsroom)

WASHINGTON — Republicans on a key U.S. Senate committee on Wednesday called on the Food and Drug Administration to wrap up its ongoing safety review of medication abortion and pressed for the Trump administration to once again require in-person dispensing.

Democrats on the Health, Education, Labor and Pensions Committee argued women, not politicians, are in the best position to determine whether to ask for a prescription for mifepristone. 

Louisiana Republican Sen. Bill Cassidy, chairman of the panel, said he hopes FDA Commissioner Marty Makary will agree to testify before the committee on the process in the future, though he didn’t set a deadline.  

“At an absolute minimum, the previous in-person safeguards should be restored and it should be done immediately,” Cassidy said. 

Republicans and anti-abortion organizations have become increasingly skeptical about the FDA’s review after news broke in December that Makary wanted to delay its release until after the November midterm elections. 

Washington Democratic Sen. Patty Murray questioned Cassidy’s reasons for holding the hearing, saying more than “160 high-quality studies have been conducted and millions of women around the world use mifepristone safely every year with fewer complications, by the way, than Viagra or penicillin.” 

Supreme Court case

Access to mifepristone, one of two pharmaceuticals used in medication abortion, which is FDA-approved for up to 10 weeks gestation, surged to the forefront after the U.S. Supreme Court ended the nationwide right to abortion in 2022. 

Many Republican state legislatures have moved to bar access to mifepristone for abortions, while Democratic states have enacted shield laws to protect health care providers who prescribe and ship it to people in states with limited or no access. 

Dr. Nisha Verma, a fellow at Physicians for Reproductive Health in Atlanta, testified before the committee that “the science on mifepristone’s safety and effectiveness is long-standing and settled.”

“Over the past 25 years, medication abortion using mifepristone and misoprostol has been rigorously studied and proven safe and effective in over 100 high-quality, peer-reviewed studies,” Verma said. “Extensive data show that medication abortion through telehealth is equally safe and effective and provides vital access for those who live in rural areas and in the growing number of maternity care deserts in the country.”

Verma contended the likely reason for the hearing was not genuine concern from Republicans about the safety and efficacy of mifepristone but “because people in this room feel uncomfortable with abortion.”

“And that’s okay, and we can talk about that,” Verma said. “And we can have an honest conversation about that and complexity and the reasons that my patients need abortion care. But we should not pretend that this is an issue of the science.”

Louisiana attorney general testifies

Louisiana Attorney General Elizabeth Murrill, a Republican, criticized the FDA’s decision during the Biden administration to allow prescriptions via telehealth and for the pharmaceuticals to be shipped, sometimes into states that bar their use. 

“Shield laws in some states protect providers from liability and effectively nullify laws in other states,” Murrill said. “Their purpose is to make it more difficult to sue or prosecute individuals in those states.”

Indiana Republican Sen. Jim Banks expressed frustration that FDA Commissioner Makary was not among the witnesses testifying at the hearing and urged the agency to release the results of its review of mifepristone quickly. 

“I’m disappointed that the FDA under Dr. Makary’s leadership hasn’t moved faster to restore the in-person dispensing requirement and strengthen the (Risk Evaluation and Mitigation Strategies) program for mifepristone,” Banks said. “I hope the rumors are false, some of them are in print, that the agency is intentionally slow-walking its study on mifepristone health risks.”

Emily G. Hilliard, press secretary for the Department of Health and Human Services, which includes the FDA, wrote in a statement the department “is conducting a study of reported adverse events associated with mifepristone to assess whether the FDA’s risk mitigation program continues to provide appropriate protections for women.”

“The FDA’s scientific review process is thorough and takes the time necessary to ensure decisions are grounded in gold-standard science,” Hilliard wrote. “Dr. Makary is upholding that standard as part of the Department’s commitment to rigorous, evidence-based review.”

Cassidy said after Banks raised his concerns that he hopes to have Makary testify “before the committee very soon and we’ve been speaking with the FDA to facilitate discussion on this and other issues.”

Cassidy added that HHS Secretary Robert F. Kennedy Jr. “did promise to come back and we have requested that he come back and testify.” 

Republicans, Family Research Council urge action by FDA

During a press conference after the hearing, Cassidy joined a handful of other GOP lawmakers and Family Research Council President Tony Perkins to further press the Trump administration to change the prescription guidelines for mifepristone. 

Perkins said the Trump administration could change FDA guidelines around how mifepristone is prescribed and distributed “overnight” if it wanted to. 

He also said it should immediately begin enforcing The Comstock Act, an 1873 law that could block shipping medication abortion.

“This is a two-step solution. One, is the in-person requirement being reestablished, the medical examinations to ensure that the women, their lives, are not put at risk,” Perkins said. “But then also … simply enforcing the law as it pertains to Comstock.”

Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz speaks at the Department of Health and Human Services in Washington, D.C., on Dec. 18, 2025. Oz and other Trump administration officials announced proposed rules that would limit gender-affirming care for minors. (Photo by Alex Wong/Getty Images)

WASHINGTON — President Donald Trump’s administration took major steps Thursday in a campaign to block minors’ access to gender-affirming care nationwide. 

Under two proposed new rules from the Centers for Medicare and Medicaid Services, hospitals would be barred from providing gender transition treatment for children as a condition of participating in Medicare and Medicaid programs, and Medicaid funding would be prohibited from being used to fund such care for minors. 

As most hospitals receive Medicare and Medicaid funding, the rules would essentially have the effect of a nationwide ban if they are finalized. 

The announcement came a day after the U.S. House passed a bill that would impose federal criminal penalties for gender-affirming care for minors and hours before it advanced a separate measure that would prohibit Medicaid funding for gender transition treatment for minors. 

The proposed regulations, which will next undergo a period of public comments, are certain to draw legal challenges.

The efforts build on Trump’s executive order in January that restricted access to gender-affirming care for kids. 

More than half of states already have laws or policies aimed at limiting youth access to gender-affirming care, according to the nonpartisan health research organization KFF. 

Health and Human Services Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Mehmet Oz announced the proposals alongside several other health officials at a press conference at HHS headquarters in Washington, D.C. 

The room featured a handful of GOP members of Congress. At least two Republican state attorneys general — Ken Paxton of Texas and Todd Rokita of Indiana — were also in attendance.

At the press conference, Food and Drug Administration Commissioner Dr. Marty Makary said the FDA is also sending “warning letters” to 12 breast binder manufacturers and sellers for “illegal marketing of breast binders for children for the purposes of treating gender dysphoria.” 

Breast binders are used to flatten tissue in the chest.  

Kennedy said his agency’s Office for Civil Rights is moving to “reverse the Biden administration’s attempt to include gender dysphoria within the definition of disability.” 

House passes anti-transgender bills 

The proposed rules are part of the Trump administration’s broader anti-trans agenda. 

Trump has signed executive orders that make it the “policy of the United States to recognize two sexes, male and female,” aimed to bar openly transgender service members from the U.S. military, and sought to prohibit trans athletes from competing on women’s sports teams consistent with their gender identity.

Meanwhile, efforts at the congressional level to restrict youth access to gender-affirming care face a dismal path in the Senate, where any legislation would likely need the backing of at least 60 senators to advance past the filibuster.

The House passed a measure Wednesday night, 216-211, that would subject medical professionals to up to 10 years in prison for providing gender-affirming care for minors. 

Rep. Marjorie Taylor Greene, who sponsored the legislation, called its passage a “win for children all over America,” in a social media post Wednesday. 

It’s likely the last legislative achievement for the Georgia Republican, who is resigning from Congress in early January. 

Four Republicans voted against the measure: Reps. Gabe Evans of Colorado, Brian Fitzpatrick of Pennsylvania, Mike Kennedy of Utah and Mike Lawler of New York.

Three Democrats voted with the GOP to back the bill: Reps. Henry Cuellar and Vicente Gonzalez of Texas and Don Davis of North Carolina.

The House also passed a measure Thursday, 215-201, from Texas GOP Rep. Dan Crenshaw and Greene that aims to prohibit “Medicaid funding for gender transition procedures for minors.” 

Cuellar, Gonzalez and Davis also backed the GOP-led bill, along with fellow Democratic Rep. Marie Gluesenkamp Perez of Washington state. 

‘Cruel and unconstitutional attacks’ 

Kelley Robinson, president of the Human Rights Campaign, an LGBTQ+ advocacy group, blasted the administration’s proposals, saying they “would put Donald Trump and RFK Jr. in those doctor’s offices, ripping health care decisions from the hands of families and putting it in the grips of the anti-LGBTQ+ fringe.”  

Robinson also emphasized that the rules are “proposals, not binding law,” and called on community members, health care providers, administrators and allies to “be vocal in pushing back by sharing the ways these proposals would be devastating to their families and the healthcare community at large.” 

The American Civil Liberties Union also condemned the administration’s proposals and vowed to challenge the efforts in court. 

Chase Strangio, co-director of the ACLU’s LGBTQ & HIV Rights Project, dubbed the proposals “cruel and unconstitutional attacks on the rights of transgender youth and their families.” 

Strangio said the proposals would “force doctors to choose between their ethical obligations to their patients and the threat of losing federal funding” and “uproot families who have already fled state-level bans, leaving them with nowhere to turn for the care they need to survive and thrive.”

A small cannabis plant. (Photo by Getty Images)

President Donald Trump’s administration is looking “very strongly” at reclassifying cannabis from the strictest category of controlled substances, Trump said Monday.

In a brief affirmative response to a reporter’s question in the Oval Office, the president confirmed he is considering a reclassification of marijuana to unlock research funding.

“A lot of people want to see it — the reclassification — because it leads to tremendous amounts of research that can’t be done unless you reclassify,” Trump said. “So we are looking at that very strongly.”

Marijuana is considered a Schedule I drug under the Food and Drug Administration’s classification of controlled substances. The FDA defines drugs on the list, such as heroin and cocaine, as lacking any medicinal value and carrying a high likelihood of abuse.

The designation carries a host of consequences, including a virtual ban on funding research for medicinal or other uses of the drug.

While marijuana use, both medicinal and recreational, is legal in many states, it remains illegal to possess or use in any amount for any reason under federal law.

Advocates have sought for decades to legalize or decriminalize the drug, which many see as less harmful than other Schedule I substances.

The growing split in recent years among many states and federal law has ramped up pressure on federal policymakers to alter the drug’s legal status.

Marijuana businesses in states where it is legal lack access to financial institutions, which cannot lend to businesses considered illegal by federal authorities.

States, meanwhile, have had difficulty regulating the environmental and health aspects of their industries.

And lawmakers, especially Democrats, have increasingly highlighted the frequent injustice of marijuana prosecutions that disproportionately affect communities of color and poor communities, though the drug is widely used across race and economic status.